Zobrazeno 1 - 10
of 407
pro vyhledávání: '"Gerald Batist"'
Publikováno v:
Current Oncology, Vol 31, Iss 10, Pp 5908-5918 (2024)
Medical oncology is a rapidly evolving field, with new medications being discovered yearly, contributing to increased survival rates. However, accessing drugs in a timely manner can be challenging. In Quebec, Canada, a physician can prescribe an unli
Externí odkaz:
https://doaj.org/article/9e2b0a11236342128a8ec77e893d37ec
Autor:
Vladimir Lazar, Eric Raymond, Shai Magidi, Catherine Bresson, Fanny Wunder, Ioana Berindan-Neagoe, Annemilaï Tijeras-Rabaland, Jacques Raynaud, Amir Onn, Michel Ducreux, Gerald Batist, Ulrik Lassen, Fin Cilius Nielsen, Richard L. Schilsky, Eitan Rubin, Razelle Kurzrock
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Dysregulated pathways in cancer may be hub addicted. Identifying these dysregulated networks for targeting might lead to novel therapeutic options. Objective: Considering the hypothesis that central hubs are associated with increased leth
Externí odkaz:
https://doaj.org/article/da12cb09d31d4454bd2113b0c027167a
Autor:
Corey S Miller, Magali Lecavalier-Barsoum, Kim Ma, Miriam Santos Dutra, Youri Kaitoukov, Boris Bahoric, Nada Tomic, Francine Dinelle, Shirin Enger, Gerald Batist, Stephen Yang, Donald Laporta, Petr Kavan, Anand Sahai, David Roberge, David Donath
Publikováno v:
Endoscopy International Open, Vol 12, Iss 10, Pp E1085-E1091 (2024)
Externí odkaz:
https://doaj.org/article/c133633817b94a959955f41f178a3c77
Autor:
David J. Stewart, John-Peter Bradford, Sandeep Sehdev, Tim Ramsay, Vishal Navani, Nigel S. B. Rawson, Di Maria Jiang, Joanna Gotfrit, Paul Wheatley-Price, Geoffrey Liu, Alan Kaplan, Silvana Spadafora, Shaun G. Goodman, Rebecca A. C. Auer, Gerald Batist
Publikováno v:
Current Oncology, Vol 31, Iss 5, Pp 2453-2480 (2024)
Countries face challenges in paying for new drugs. High prices are driven in part by exploding drug development costs, which, in turn, are driven by essential but excessive regulation. Burdensome regulation also delays drug development, and this can
Externí odkaz:
https://doaj.org/article/e2a0bda42f934ee6ba8bb491b5743aa9
Autor:
Karen Gambaro, Mélanie Groleau, Suzan McNamara, Arif Awan, Maged Salem, Mahmoud Abdelsalam, Eve St-Hilaire, François Vincent, Julie Carrier, Helen MacKay, Louise Provencher, Dominique Boudreau, Zineb Hamilou, Fred Saad, Cristiano Ferrario, Gerald Batist, Maud Marques
Publikováno v:
Journal of Pharmacy & Pharmaceutical Sciences, Vol 26 (2023)
There is an increasing demand for real-world data pertaining to the usage of cancer treatments, especially in settings where no standard treatment is specifically recommended. This study presents the first real-world analysis of third-line treatment
Externí odkaz:
https://doaj.org/article/feab0871603e4619976a4a6c0af8c91a
Autor:
Tahar Aboulkassim, Xiaohong Tian, Qiang Liu, Dinghong Qiu, Mark Hancock, Jian Hui Wu, Gerald Batist
Publikováno v:
Cell Reports, Vol 42, Iss 9, Pp 113104- (2023)
Summary: NRF2 (nuclear factor erythroid 2-related factor 2) is a master regulator of protective responses in healthy tissues. However, when it is active in tumor cells, it can result in drug resistance. KEAP1, the endogenous NRF2 inhibitor, binds NRF
Externí odkaz:
https://doaj.org/article/5432f75a297e4e659b80fb929a830c8e
Autor:
Karen Gambaro, Maud Marques, Suzan McNamara, Mathilde Couetoux du Tertre, Cyrla Hoffert, Archana Srivastava, Anna Schab, Thierry Alcindor, Adrian Langleben, Lucas Sideris, Mahmoud Abdelsalam, Mustapha Tehfe, Felix Couture, Gerald Batist, Petr Kavan
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 1, p 43 (2023)
Single-agent regorafenib is approved in Canada for metastatic colorectal cancer (mCRC) patients who have failed previous lines of therapy. Identifying prognostic biomarkers is key to optimizing therapeutic strategies for these patients. In this clini
Externí odkaz:
https://doaj.org/article/ec86c695c34645c382ed30a6f5995a36
Autor:
Vladimir Lazar, Baolin Zhang, Shai Magidi, Christophe Le Tourneau, Eric Raymond, Michel Ducreux, Catherine Bresson, Jacques Raynaud, Fanny Wunder, Amir Onn, Enriqueta Felip, Josep Tabernero, Gerald Batist, Razelle Kurzrock, Eitan Rubin, Richard L. Schilsky
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: The current model of clinical drug development in oncology displays major limitations due to a high attrition rate in patient enrollment in early phase trials and a high failure rate of drugs in phase III studies. Objective: Integrating t
Externí odkaz:
https://doaj.org/article/59159a57b2d143e3be0bcdbaf9afc021
Autor:
Alan Kaplan, David J. Stewart, Gerald Batist, Silvana Spadafora, Sandeep Sehdev, Shaun G. Goodman
Publikováno v:
Current Oncology, Vol 29, Iss 4, Pp 2504-2508 (2022)
The government of Canada now plans to bring into force new federal drug pricing regulations on 1 July 2022. We do not take issue with the goal of medication affordability, which is vital in healthcare the world over. Our concern is that the new guide
Externí odkaz:
https://doaj.org/article/a9184a0365814b0a8d59816e3141c8de
Publikováno v:
Current Oncology, Vol 29, Iss 2, Pp 1176-1189 (2022)
New drugs are expensive, in part due to excessive drug development costs. Governments are trying to reduce drug prices. This can delay access to effective agents. A country’s access to new drugs correlates with prices they agree to pay. After Healt
Externí odkaz:
https://doaj.org/article/2adbf68245f449369d3ac09fffd64189